This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A single-center study designated to evaluate the tolerance and efficiency of two different aerosol delivery systems to administer FDA-approve NebuPent, the aerosol form of pentamidine (AP) in patients with cystic fibrosis. The objectives of this study are to evaluate the tolerability of AP delivered from the Aerogen Clinical inhaler device compared to delivery with the FDA-approved Respirgard II aerosol delivery device. In addition to tolerability, pharmokinetic data will be acquired to support future dosing and eff
Showing the most recent 10 out of 1825 publications